Therapy Name | Abemaciclib + Exemestane |
Therapy Description |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Abemaciclib | Verzenio | LY2835219 | CDK4/6 Inhibitor 8 | Verzenio (abemaciclib) is a dual CDK4/6 inhibitor, which inhibits Rb1 protein phosphorylation and may induce cell cycle arrest and prevent growth in cancer cells (PMID: 24919854). Verzenio (abemaciclib) is FDA approved as a monotherapy and in combination with Faslodex (fulvestrant) in patients with hormone receptor-positive (ESR, PGR) and ERBB2 (HER2) receptor-negative advanced or metastatic breast cancer (FDA.gov). |
Exemestane | Aromasin | Aromatase Inhibitor 3 | Aromasin (exemestane) is an aromatase inhibitor, which prevents the conversion of androgenic precursors to estrogens (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT02057133 | Phase I | Abemaciclib + Letrozole Abemaciclib + Exemestane Everolimus + Exemestane + LY2835219 Abemaciclib + Anastrozole Abemaciclib + Tamoxifen Abemaciclib + Trastuzumab | A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread | Recruiting |